NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

NEW YORK – A University of Michigan lab has developed a blood-based test to detect recurrence of human papilloma virus-positive head and neck cancer sooner than standard-of-care imaging and clinical ...

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

Highlights from the first day included updates from several firms about their China businesses and M&A strategies.

Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

NEW YORK – Dublin-based firm Novus Diagnostics said on Wednesday that it has secured €4.6 million ($4.7 million) in an equity financing round to support the development of its point-of-care testing ...

Solomon Moshkevich, Natera's president of clinical diagnostics, said that the firm has seen strong growth in MRD testing in 2023 and 2024 that has been driven by both new physician users and existing ...

The proteomic blood test could be a noninvasive tool used to improve detection of the condition, which currently takes an average of 7.5 years to diagnose.

The firm will use its blood-based tests to explore connections between Alzheimer's disease and neuronal α-synuclein conditions including Parkinson's disease.

Sapient will be an Alamar certified service provider for Alamar's NULISAseq Inflammation panel and its NULISAseq CNS Disease panel.